Li Hong, Wu Qiong, Li Ting, Liu Changhao, Xue Lin, Ding Jie, Shi Yongquan, Fan Daiming
State Key Laboratory of Cancer Biology and Xijing Hospital of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.
Oncotarget. 2017 Jul 11;8(28):45060-45071. doi: 10.18632/oncotarget.15023.
Intestinal metaplasia is considered to be a pre-cancerous lesion of gastric cancer. The miR-17-92 cluster was previously reported to have clinical value in the prediction of cancer development. This study aimed to test the diagnostic value of miR-17-92 in gastric cancer and the intestinal metaplasia patients compared with the normal ones.
The results showed that miR-17-92 members were over-expressed in the serum of both gastric cancer and intestinal metaplasia patients, compared with healthy controls. Serum miR-17-92 members could also distinguish patients with gastric cancer and intestinal metaplasia from healthy controls.
Serum miR-17-92 expression levels were detected using quantitative real-time PCR in 75 patients with gastric cancer, 104 patients with intestinal metaplasia and 38 healthy controls. The Receiver operating characteristic (ROC) curves and the area under the ROC curve (AUC) were then analyzed to test the efficacy of the miR-17-92 members in distinguishing gastric cancer, intestinal metaplasia and healthy controls.
In conclusion, the miR-17-92 cluster might be useful as a potential serum biomarker for the early detection of gastric cancer.
肠化生被认为是胃癌的一种癌前病变。先前报道miR-17-92簇在预测癌症发展方面具有临床价值。本研究旨在检测miR-17-92在胃癌及肠化生患者与正常人群中的诊断价值。
结果显示，与健康对照相比，miR-17-92成员在胃癌和肠化生患者血清中均呈过表达。血清miR-17-92成员也能够将胃癌和肠化生患者与健康对照区分开来。
采用定量实时PCR检测75例胃癌患者、104例肠化生患者及38例健康对照血清中miR-17-92的表达水平。然后分析受试者工作特征（ROC）曲线及ROC曲线下面积（AUC），以检验miR-17-92成员区分胃癌、肠化生和健康对照的效能。
总之，miR-17-92簇可能作为一种潜在的血清生物标志物用于胃癌的早期检测。
